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INTRODUCTION 
Tuberculosis infection is rampant in a country like India. Tuberculosis 
prevalence is stable, but there has been increased incidence due to 
increasing incidence of Human immunodeficiency virus infection. In 
2004, there was an estimated 5.134 million people living with 
HIV/AIDS in India. The tuberculosis incidence was 1.8 million per 
year.  In recent years, human immunodeficiency virus infection has 
turned out to be the most important risk factor for active tuberculosis 
in patients with mycobacterial tuberculosis infection. 
Retroviral diseases pose a great problem to both the control 
programmes of both Human immunodeficiency control programmes 
as well as for pulmonary tuberculosis programmes. In controlling 
tuberculosis and HIV co infection, controlling HIV by highly active 
anti-retroviral therapy (HAART) will control the new incidence of 
tuberculosis.  WHO started a campaign 3 by 5 in 2004 to make 
HAART available to resource limited areas. 
In patients with retroviral disease and Koch’s disease, the risk of 
developing tuberculosis is 10% per year. There is a synergistic 
relationship between Tuberculosis and Retroviral disease HIV. 
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Human immunodeficiency virus infection accelerates the progression 
of tuberculosis and makes it more resistant to treatment. 
Mycobacterium tuberculosis infection accelerates the retroviral 
disease progression.  We shall discuss the pathogenesis of co-
infection of retroviral disease with Koch’s disease, its epidemiology, 
and clinical aspects emphasizing on the spectrum of tuberculosis with 
relation to degree of immunosuppression. 
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AIMS and OBJECTIVES 
 
I. To describe the various clinical manifestations of TB in people 
living with HIV and AIDS (PLHA) and to correlate it with the 
degree of immunosuppression. 
 
II. To Correlate CD4 cell count and TB spread. 
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A. REVIEW OF LITERATURE 
A.1 SOURCE OF LITERATURE 
The literature source for review of our study was taken from 
published studies describing the pattern of disease spread, treatment 
protocols and its occurrence. Priority was given to more recent 
studies and older studies were used when no other data is available. 
Articles published in English were only used. WHO site and Medline 
were the main electronic data used for the review of literature.  
Indian studies were given priority and global scenario was used for 
comparison. Studies about co-infection and drug treatment strategies 
employed were appraised from few articles. The aim of selecting the 
literature review was to fill the gaps in knowledge regarding co-
infection. The main limitations were the lack of convincing studies 
from India regarding the present status of the coinfection with 
retroviral disease and pulmonary tuberculosis. 
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A.2 AETIOLOGY OF TUBERCULOSIS 
Tuberculosis was discovered by Robert Koch in the year 1895. He 
submitted his paper Etiology of tuberculosis to the physiological 
society of Berlin. Discovery of the bacilli, its acid fast nature and the 
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experiments with inoculation led to rapid advancements in 
understanding the pathogenesis of Tuberculosis1. 
Tuberculosis is caused by Mycobacterium tuberculosis complex. The 
complex includes M.tuberculosis, M.bovis, M.microti, M.canetti and 
M.africanum. M.canetti was recently discovered and it can also cause 
infection in human beings. 
Opportunistic mycobacteria or the atypical mycobacteria includes 
M.avium and M.intracellulare. Atypical mycobacteria are particularly 
important in immunocompromised patients. 
Mycobacterium tuberculosis complex are distinguished using 
microbiological tests. It is a slow growing organism, needs optimal 
temperature for its growth and it is a facultative anaerobe.  
A.3 TUBERCULOSIS - PATHOGENESIS 
Risk factors for acquiring tuberculosis are people from low 
socioeconomic status, living in crowded places, Human 
immunodeficiency virus infection. The sites usually involved by 
tuberculosis is Pulmonary and extra-pulmonary sites. The common 
extra-pulmonary Lymph node, bone, joints, genito-urinary, meninges 
and gastrointestinal system. 
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It is transmitted from person to person by inhalation of aerosol and 
droplet. The other methods of transmission are by consumption of 
unpasteurized milk (M.bovis) and by inoculation. Trans-placental 
route of transmission has been reported2.  
A.4 PRIMARY TUBERCULOSIS 
The progression of clinical disease depends on the immune status of 
the individual. 
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Patient with pulmonary tuberculosis are the main source of infection 
to the public. The particle size of the droplet is 1-5 micrometers 
containing the bacilli. Usually patients who are secreting active bacilli 
in sputum are said to have active e pulmonary tuberculosis. The 
droplet size being as small as one to five micrometer can stay in the 
atmosphere for a longer time approximately for few hours. 
In immunocompetent individual the disease pathogenesis depends 
on 3 factors 
a) Number of M.tuberculosis organisms involved. 
b) Infecting dose and the virulence of the organism 
c) The development of cell mediated immunity 
Th1 cell is the primary cell which is involved in cell mediated 
immunity. 
Disease in immunocompetent disease naïve individual almost always 
begins in the lungs. Inhaled bacilli usually gets deposited in the distal 
airspaces in lower part of upper lobe and upper part of lower lobe 
.The mycobacterium bacilli is then internalized by the pulmonary 
alveolar macrophages. Other cell groups are also affected namely the 
pneumocytes. These are the epithelial cells in the alveoli. The 
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mycobacterium which is taken up by the phagocytes start replicating 
within the macrophage itself. After replication, it starts spreading to 
the lymph nodes. Initial lesion is called Gohn focus where there is a 1 
to 1.5cm consolidation which often caesates3. 
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In patients who are infected with mycobacterium tuberculosis bacilli, it 
usually takes few weeks for the immune response to start the 
response. The activated T- lymphocyte stimulates macrophages, and 
other immune cells which start forming granuloma’s in an attempt to 
wall of the infection. The bacilli is not destroyed, rather contained 
within the granulomas. This is the proof for the existence of the term 
Latent Tuberculosis infection, where in the bacilli in the caeseating 
granulomas are not destroyed rather are dormant. They can be 
activated at a later stage in the event of a defect in the cell mediated 
immunity. 
Getting into more detail, the Antigen presenting cells recognize the 
pathogen associated molecular patterns (PAMP) by specific 
pathogen recognition receptors (PRR). The host cell identifies the 
bacilli through different antigens4. 
1. Toll like receptors (TLR) 
2. Nucleotide binding oligomerization domain like receptors (NLR) 
3. C-type lectins 
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There are few specific molecules which are included as C-type 
lectins. These include mannose receptor, DC-SIGN cells (Dendritic 
cell- specific intercellular adhesion molecule grabbing nonintegrin and 
dectin-1. The non-immune cells namely, fibroblast and epithelial cell 
also express Toll like receptors (TLR). 
The interaction between toll like receptor and the bacilli have a variety 
of consequences and may end up either being beneficial to the host 
or the pathogen. 
The Toll like receptors play a very important role in the microbial host 
interaction. The toll like receptor 2 and 4 are key components in the 
internalization of mycobacterium tuberculosis. The different gene 
polymorphisms of the TLR are the reason for the varied response of 
the individual to the bacilli. 
The tubercular bacilli contain few unique mixture of lipids and 
glycoproteins which contain very high levels of mycolic acid in its cell 
walls. The notable few are 
1. 19 and 27 kilo Dalton lipoproteins. 
2. 38 kilo Dalton glycoprotein 
3. Lipomannan  
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4. Mannose capped lipoarabinomannan  
These result in interaction with the TLR which causes transcription 
and release of various cytokines which are responsible for pro 
inflammatory reaction5. 
The normal anti-inflammatory response mounted by the body in 
response to this pro inflammatory cascade is by tyrosine kinase 
receptor family called Tyro3/Axl/Mer (TAM).This is a TLR mediated 
negative feedback mechanism. Mycobacterium tuberculosis uses this 
to its advantage. The 19 kilo Dalton lipoprotein acts similar to TLR 2 
and modulates its function. It downregulates the activation of the 
infected macrophage and hence evades immunity. There is 
insufficient presentation of antigen to the effector CD4 cells which 
leads to decrease in inflammatory cytokines. 
On a similar note, the mannose receptor lipoarabinomannan inhibits 
phagolysosome formation within the macrophage hence, prevents the 
destruction of the bacilli within the macrophage. 
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All these events are taking place within the pulmonary alveolar 
macrophages. The bacilli trying to escape and evade the immunity 
and the host trying to control the infection. The Dendritic cell with the 
antigen travel to the lymph node and activate the CD4 and CD8 
lymphocytes and prime them, the CD4 and CD8 cells then travel to 
the infected site, attracted by the chemokines released by the 
infected macrophages. There they attract macrophages and 
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fibroblasts, epithelial cells etc. in an attempt to control the infection by 
the formation of the granuloma. 
Within the granuloma the CD4+ t cells secrete Gamma interferon (Y-
IFN). This helps the host to wall off the infection. The bacilli are 
facultative anaerobes, so cannot survive with low oxygen tensions 
within the granuloma. However some bacilli do stay dormant within 
the granuloma. The central zone of the granuloma typically consists 
of casseous material which is made up by dead macrophage and the 
bacilli. The wall of the granuloma is made up by epithelial cells, 
macrophages and fibroblasts. The walls of the latent tuberculosis is 
made up of more of fibroblasts than macrophages6. 
The granuloma microenvironment is very complex. The low oxygen  
Tension, increased levels of nitric oxide and carbon monoxide are 
involved transcription of various factors within the tubercle bacilli that 
help in sporulation and dormancy. The granuloma walling off effect 
can be clinically utilized by the delayed type hypersensitivity reaction 
for purified protein derivative test. This is called the tuberculin skin 
test. 
The cells which play an active part in controlling the infection is  
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1. Macrophages 
2. Dendritic cells 
3. αβ-T cells (both CD4+ and CD8+) 
4. CD1 restricted T cells 
5. Natural killer cells 
These cells especially CD4 cells elaborate the central key cytokine 
gamma interferon which activates macrophages. There has been 
reports of gamma interferon independent pathway also. Thus 
depletion of CD4 plays an important role in reactivation of 
tuberculosis. 
The CD4 helper T cell orchestrates these immune functions through  
1. Fas-FasL interaction which causes apoptosis of the infected 
macrophage. 
2. Production of inflammatory cytokines namely IL2 and TNF 
alpha. 
3. Helps CD8 helper cell enhancing its cytotoxic ability by 
increasing IL-15 levels. 
4. Produces nitric oxide, whose exact role in control of TB is yet to 
be established. 
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The CD8 helper T cell plays its part during the control of infection in 
the latent Tuberculosis and the reactivation of tuberculosis. Its role in 
primary Tuberculosis is not convincingly studied. It kills the 
M.tuberculosis bacilli directly by releasing granulysin. 
CD1 T cells and T αβ-T cells play a small role in presenting the lipids 
and lipopeptides to the CD4 helper T cells.    
The gamma interferon produced by CD4 cells, NK cells and 
macrophages help in augmenting the antigen presentation to the 
Helper CD4 cells. It does this by transcription of more than over 200 
genes which upregulate MHC class 2 expression. TNF alpha and 
nitric oxide production is also very important as they produce reactive 
nitrogen intermediates which help in killing the bacilli. They also play 
a role in preventing the apoptosis of memory T cells. 
TNF or the tumour necrosis factor alpha secreted by the activated 
CD4 t helper cell is a cytokine which acts synergistically with gamma 
interferon in augmenting the response against the mycobacterium 
bacilli. It is an important immunomodulation. Studies show that mice 
deficient in tumour necrosis factor alpha or gamma interferon or IL2 
do not mount satisfactory response against the mycobacterium. The 
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TNF alpha stimulates the secretion of cytokines like MCP and 
RANTES7. 
Mycobacterium counteracts these host reactions by its main method 
of evading immunity. It does so by inhibiting the antigen presentation 
to the macrophages. The mannose Lipo arabino mannan and the 19 
kilo Dalton lipoprotein downregulate the gamma interferon induced 
genes. It also plays a role in inhibiting MHC class 1 antigen 
processing via Toll like receptor (TLR).By chronically downregulating 
the antigen processing, it makes time for itself to multiply, as it is a 
slow growing bacilli. 
The mycobacterium bacilli counteracts the antimicrobial action of 
nitric oxide and reactive nitrogen intermediates by having an enzyme 
alkyl peroxide reductase. The T-cells and the macrophages elaborate 
the Nitric oxide inside granuloma’s using the enzyme iNOS (Nitric 
oxide synthetase) this results in formation of nitrotyrosine and 
peroxynitrite which are toxic to the bacilli. This is all proved in studies 
where knockout mice for iNOS were susceptible for the reactivation of 
latent TB. This also proves that though Reactive nitrogen 
intermediates are important in controlling tuberculosis, it is not 
sufficient by itself. 
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There are exists a protein in the tubercle bacilli, a protein akin to our 
hemoglobin called glbN and glbO. Bacilli which lack these genes are 
highly susceptible to attack from RNI or the reactive nitrogen 
intermediates. 
 
The formation of phagolysosome within the macrophage is essential 
step in the host defense for killing the bacilli. It takes place by a 
fission fusion event that remodels the membrane and recruitment of 
vacuolar proton transporting ATPase. This lowers the internal ph. 
which helps in killing the bacilli. Calcium plays a role in signaling 
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cascade. The rise in intracytosolic calcium, cascade leads to the 
culmination of activation of PI-3K and leads to fusion of lysosomal 
membrane to endosome which forms the phagolysosome.  
The Mycobacterium secrete  
1. Mannose lipoarabinomannan Man LAM 
2. SecA2 protein  
3. NADH dehydrogenase 
4. Two proteins – Rv3654c and Rv3655c 
These help the Mycobacterium bacilli in evading immunity, by 
preventing apoptosis of the infected macrophage. If not for these 
proteins, the infected macrophage would have been destroyed, 
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because it would have been activated to undergo apoptosis by the 
CD8 T Cell8. 
From the above discussions it is evident that the mycobacterium 
bacilli have enough tricks in its arsenal to evade the host immunity. 
These have been extensively studied in experiments, where either 
they have injected these genes from a pathogenic mycobacteria into 
a non-pathogenic strain or by injection knockout mice with these 
strains. Now after evading the immunity, it stays within the granuloma 
only to be reactivated at a later stage. 
The process of reactivation is complex. The most important risk factor 
as it is already elaborated is the depletion of CD4 t cells and CD8 T 
cells by the HIV virus. After this is done, there are several factors 
which trigger the dormant TB bacilli to get reactivated once again. 
The Mycobacterium produces a lot of proteins and made sure that 
lots of gene are there for one purpose, to ensure the survival of the 
bacilli within the macrophage. Weakening immune system typically 
due to HIV, but can also occur in other conditions namely debility, 
elderly individual, Post-transplant patients on immune suppression, 
immunomodulatory drugs, and diabetic patients. 
30 
 
The reactivation typically involves the upper lobes where there is a 
higher ventilation compared to perfusion. This supports good bacillary 
growth. The bacilli contain certain enzymes which are lytic 
transglycolases and resuscitation promoting factors and 
endopeptidases. These help the bacilli to get reactivated. 
 
Latent Tuberculosis is the non-replicating bacilli within the granuloma 
which becomes activated under favorable conditions. They cause 
active tuberculosis. During the dormant phase, the bacilli stop 
replicating inside the granuloma due to the low pH and the hypoxic 
environment, much before the immune system action could start. This 
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is similar to the bacteriostatic culture in which mycobacterium is 
grown exogenously. These non-replicating bacilli are resistant to 
killing. 
The non-replicating bacilli are taken up by the foam laden 
macrophages which travel along with the macrophage and enter 
various parts of the lung. In this process re-infection of the upper 
lobes fare a better chance of reactivation of the resistant bacilli 
because of the higher oxygen tension. The subsequent reactivation in 
an immunocompetent individual leads to an array of inflammatory 
cascade that leads to liquefaction, caseation and cavitation of the 
upper lobes.  
 Figure: - cavitation Left Upper lobe  
This is similar to the phenomenon of IRIS or the immune 
reconstitution inflammatory syndrome, wherein in HIV patients, the 
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initiation of treatment suddenly boosts the CD4 cell count and the 
individual is suddenly able to mount a good immune response to the 
previously tolerated bacillary replication which went unchecked. This 
is supported by the cohort analysis of the national study of 
tuberculosis9. 
The diagnosis of the latent tubercular bacilli is done by delayed type 
hypersensitivity. We inject a cocktail of antigens from the tubercle 
bacilli. This is known as purified protein derivative (PPD). When 
rechecked after 48 hours, if the induration is more than 5 mm is 
considered positive in HIV positive individuals. Since in Asia there are 
many people who are exposed to atypical mycobacteria, the 
induration more than 10 mm is considered positive.  
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More than 20 mm in duration is considered to be as having active 
disease. Negative test that is less than 5 mm when checked after 48-
72 hours it could be due to anergy also. It might be in conditions 
where the CD4 helper cells are defective. BCG vaccination can cause 
false positive reactions. 
There are better tests to diagnose latent infections. The next one 
which was developed was gamma interferon assay. This targeted 
early secreted antigenic target -6 and culture filtrate protein 10.The 
next technology which was developed are the flow cytometry. It 
requires less than one milliliter of blood for the analysis. 
Quantiferon GOLD and SPOT TB are the two commercially based 
samples. They utilize the above mentioned target antigens namely 
ESAT6 and T cell themselves. The recent advancement in these 
were the Quantiferon GOLD in tube. IT also utilizes the TB 7.7 also. 
Although few of these tests cannot distinguish between the active TB 
and the Latent TB, they are very helpful in detecting active TB in 
immunosuppressed individuals. They are also of more benefit to 
countries where Mycobacterium tuberculosis incidence is low. In 
countries with high endemicity, it is only of moderate value. 
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B. HIV- HUMAN IMMUNODEFICIENCY VIRUS 
B.1 EPIDEMIOLOGY AND AETIOLOGY 
HIV or the human immunodeficiency virus belongs to lentivirus group 
of retroviruses. It was discovered in early 1980’s. Two types of 
viruses were identified and the HIV 2 was only seen in West Africa, 
although a spread has been reported in recent years. Around 1980 
patients who had lymphadenopathy were evaluated and for the first 
time in Pasteur institute the T cells were cultured and the HIV 
infection was discovered. Phylogenetic analysis of certain earlier 
isolates show that HIV 1 was prevalent even before the AIDS 
pandemic. HIV 1 the common infectious agent is further sub 
classified into M, N and O. M type causes the global burden of HIV.  It 
is further subdivided into A-D, F-H and K subgroups. HIV 2 is less 
virulent than HIV 1.  
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HIV was initially a zoonotic infection. It is very similar to simian 
immunodeficiency virus which should have first infected the bushman 
hunters.  HIV type C is the commonest subtype in West Africa and 
India. Subtype B is common in America and Western Europe. 
 
All these are due to the spontaneous mutation of the reverse 
transcriptase enzymes .Transmission of HIV 2 is very slow and 
attenuated.  In around 2012 the global estimate of HIV was 35.3 
million. Most of the prevalence comes from Sub Saharan Africa. The 
recently introduced HAART the highly active anti-retroviral therapy 
has reduced the incidence the HIV. After WHO campaign around 10 
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million people from low income and middle income countries had 
started having availability to anti-retroviral therapy .Reduction in 
homosexual transmission, through awareness and decrease in 
injection needles, recycling of injection needles saw a declining trend 
of HIV both in developing and developed countries. In western 
countries, the main transmission was through Men who have sex with 
men (MSM) 10. 
They were given awareness of the high risk behavior, receptive anal 
intercourse recipients were given HAART, and the stigmata to receive 
care was taken care of. The number of children suffering from HIV 
and AIDS is huge, around 38 %. This is due to mother to child 
transmission, and the lower availability of HAART to children who do 
not seek treatment. 
B.2 HIV-1 TRANSMISSION 
HIV transmission occurs through 
1. Sexual transmission 
2. Blood and blood products 
3. Vertical transmission from mother to child 
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The most important determinant in risk of sexual transmission is the 
number of viral copies in the fluid. Risk can be minimized if the 
amount of viral copies can be decreased logarithmically. Acute HIV 
infection have very high viral loads which propagate HIV epidemic 
.The other problem which increase the risk of transmission is the 
presence of other sexually transmitted diseases. Male circumcision 
seems to provide effective protection against STD. 
Behavioral factors like having many sexual partners also seemed to 
increase the risk of acquiring HIV infection. A simple measure of 
wearing protective contraceptives like condom can decrease the risk 
of transmission of HIV. Women represent 57 % of the population 
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living with HV. Increasing high risk behavior among women, 
increasing alcoholism smoking and IV drug use and the stigma to 
search treatment cause problems in women with HIV. 
 
The virus has a diameter of 100-120 nanometer with a spherical 
morphology. It has a truncated core with a lipid core. The core 
contains 2 copies of single stranded RNA, along with the enzymes 
protease, integrase and reverse transcriptase. The viral genome is 
9.2 kilo base pairs long and contains 3 structural, 2 envelope and 3 
genes for enzymes. It is a single stranded positive sense RNA. Their 
ends are covered by polyadenylated caps which prevents it from 
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enzyme degradation. There is an element called tyrosine RNA which 
acts as a primer of viral RNA11. 
 
The Human immunodeficiency virus contains the genes called the 
regulatory genes. These help the virus to produce proteins and help 
the virus from infection and replication. 
TAT gene – Tran’s activator of transcription is a regulatory gene 
which is encoded by 2 different exons. It codes for a protein which is 
102 Amino acid long. IT acts through TAT –receptor binding which 
activates viral transcription. When it is shed into circulation, there is a 
chance of development of antibody to this protein. It however induces 
apoptosis of both CD4 cells which are infected and those which are 
not infected. It can act as a neurotoxin, which is shown in vitro 
experiments. 
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REV gene– It is another regulatory gene which forms an essential 
accessory protein whose function is to transport mRNA. Rev 
dependent RNA transport is important for early and late phases of 
viral replication. 
VIF gene – viral infectivity factor  
It produces a 23 kilo Dalton protein found I the cytoplasm. It helps the 
virus to infect cells which contain CD4 receptors. The mechanism of 
action is less clear. The viruses with no Vif gene infect other cells at 
least 25 times slower than other viruses. 
NEF gene – negative factor, produces a 27 kilo Dalton protein. It 
helps in downregulation of the receptor expression and enhances 
infectivity of the virus. Nef Phenotypes of the viruses are present but 
not understood to a large extent. 
VPU gene – viral protein U, It produces a protein which is 81 amino 
acids long. It is a membrane protein which also encodes envelope 
and regulated by Rev. It helps in release of viral particles from 
plasma membrane of infected cell and degrades CD4 in the 
endoplasmic reticulum. 
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VPR gene – viral protein R, produces a protein which is 96 amino 
acids long one more protein 14 kDa responsible for G2 cell cycle 
arrest thought to indirectly enhance viral replication by increasing 
transcription from LTR. Vpr expression causes breaks in the nuclear 
lamin structure, which weakens nuclear envelope and interferes with 
DNA synthesis thus cycle arrest prior to mitosis. It is also implicated 
in facilitating infection of non-dividing cells, mostly macrophages. Vpr 
also functions to connect the pre-integration complex to the cellular 
nuclear import machinery12.  
B.3 PATHOGENESIS 
THE NATURAL CYCLE OF HUMAN IMMUNODEFICIENCY 
VIRUS 
HIV targets CD4 T lymphocytes, the virus entry is complex. The entry 
requires the CD4 cells to interact along with a chemokine receptors. 
There are 2 receptors CCR5 and CXCR4. Monocytes, macrophages 
and dendritic cells also contain these receptors. HIV entry into the 
astrocytes and the renal epithelial are the only cells that are HIV 
independent. There are 2 phases of the cycle. The first phase is the 
entry into the host cell. The second phase is the integration of the 
virus into the genome. 
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There are two phases in latency of the virus. 
1. Pre integration latency 
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2. Post integration latency 
Pre integration latency – there is generation of viral DNA before the 
integration to the host.  
Post integration latency – refers to the lack of viral replication after 
the viral DNA into host genome. 
Virus enters the host through the CD4 and CXCR4 and CCR5 
chemokine receptors. As a result the contents of the core are 
released, the enzyme reverse transcriptase and integrase. Viral 
protein R help the virus to integrate the viral DNA into host genome 
by aiding the transport into the nucleus.  
During the early phase of replication only the mRNA encoding the 
TAT REV and NEF genes are transcribed, and their proteins are sent 
out into the cytoplasm. The amount REV gene function translates into 
the amount of spliced mRNA.  
The viral RNA REV complex is then transported across the nuclear 
membrane back and forth where it utilizes Guanosine triphosphate for 
its energy. 
The late phase of replication involves both rev dependent and rev 
independent pathways.  Ribosomal frameshift mechanism is involved 
in creating some of the gag pol precursor13. 
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ASSEMBLY AND BUDDING 
Inside the macrophages inside the cytoplasm, assembly of the virus 
particles takes place.  The gag gene product is cleaved into matrix, 
capsid, nucleocapsid which associates into a virion spontaneously. 
Cyclosporine inhibits the association of Virions with cyclophilin. 
The envelope is formed by the gene product of ENV. Then it is 
cleaved into gp120 and gp41.GaG products forms the encapsidation. 
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REVERSE TRANSCRIPTASE ENZYME 
The enzyme has no proofreading activity and accumulates mutation 
at a rate of 104 – 106   and each time it replicates it destroys nearly 2 
billion CD4 cells per day. The half-life of a free virus is 6 to 8 hours 
approximately14. 
B.4 CLINICAL FEATURES  
The Human immunodeficiency virus can have protean 
manifestations, it can range from completely asymptomatic individual 
to completely debilitated individual. Patients can remain without any 
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significant symptoms for about 8 to 10 years. This is because of the 
long incubation period of HIV.  As HIV advances depleting the CD4 
cells, the first manifestations may be the initial Opportunistic 
infections. These diseases are very uncommon in any normal or 
immunocompetent individual. Human immunodeficiency virus per se 
can cause severe debilitation and death. Opportunistic infections 
includes both infective and cancerous conditions. The better term to 
use would be opportunistic conditions. The infections seen in HIV 
infection are many. They can be classified as bacterial, viral, parasitic 
and fungal. 
The frequency of opportunistic infections are dependent on the 
geographic conditions. Overall Tuberculosis is the commonest 
opportunistic infections. Other common infections seen are 
pneumocystis jirovecii, CNS infections which are common are 
Tuberculoma, tuberculous meningitis and Primary CNS lymphoma. 
Visceral leishmania are common in some areas of Bihar. According to 
degree of immunosuppression clinical phases can be differentiated 
into primary, early, intermediate and advanced HIV infection. 
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PRIMARY HIV INFECTION 
The initial presentation of HIV infection is similar to an ordinary viral 
infection. Fever, skin rash, headache and diarrhea. As soon as viral 
replication occurs, there is a drastic fall in CD4 cell count. The viral 
load increases rapidly and forms a set point15.  
 
During this phase patients are extremely infectious. This is of no 
clinical value. Patient usually doesn’t come to hospital at this stage as 
there is no significant clinical deterioration. 
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PRIMARY HIV INFECTION – COMMON CLINICAL FEATURES 
General Dermatology CNS GIT Lungs 
Pyrexia 
 
Sore throat 
 
Enlarged 
lymph 
nodes 
 
Joint pain 
 
Muscular 
pain 
 
Fatigability 
 
Loss of 
appetite 
/weight loss 
Rash 
 
Itching 
 
Mucocutaneous  
ulceration 
 
Hair loss 
Headache 
 
Kernigs sign 
 
Peripheral 
neuropathy 
 
Radicular 
pain 
 
GBS 
 
Cognitive 
disorders 
Candidiasis 
 
Nausea/ 
vomiting 
 
Loose 
stools 
Cough 
EARLY IMMUNODEFICIENCY  
Patients with CD4 count <500 cells/cubic millimeter are considered to 
be in this stage. In this stage usually more of autoimmune diseases 
and neurological illness have seemed to occur. Diseases like Bell’s 
palsy, acute inflammatory demyelinating polyneuropathy, chronic 
inflammatory demyelinating polyneuropathy and Bell’s palsy have 
seemed to occur. 
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CD4 decline and the clinical picture 
INTERMEDIATE IMMUNODEFICIENCY 
 Patients with CD4 count between 200 and 500 cells/cubic millimeter 
are considered to be in this stage. In this stage the commonest 
infection seen are the seborrheic dermatitis, molluscum contagiosum, 
herpes zoster, sinusitis, gingivitis16. 
ADVANCED IMMUNODEFICIENCY 
Patients with CD4 count less than 200 cells/cubic millimeter are 
considered to be in this group. This gives rise to very advanced 
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immunodeficiency which causes some abnormal pathogens to affect 
the individual. Like Oral hairy leucoplakia, candidiasis, 
cryptococcosis, Mycobacterium avium complex. 
 
WHO STAGING 
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WHO started large number of campaigns once AIDS pandemic 
started, its famous campaign is 3 by 5 among all the undertakings. 
The clinical staging was bought on to help the countries where CD4 
testing was not available or affordable. 
B.5 LABORATORY DIAGNOSIS 
The laboratory diagnosis is taken from a source which is meant for 
the State government. It is offered to all people who approach the 
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centers counselling called ICTC. The center here in Madras medical 
college follows the national AIDS program algorithm. The first 
guidelines were given in 1989 for the diagnosis of HIV by the Centre 
of disease Control. They also started testing for HIV 2 but was not 
useful for our country. This was started in the year 1992. The most 
recent international update regarding this was started in the year 
2014. The updates include tests for HIV antigens and newer 
antibodies. HIV nucleic acid tests are included specially. This is to 
prevent the people who may be in window period, in an area of high 
prevalence, this is very important as this percentage might contribute 
to a huge amount of people17. 
These are the purposes of HIV testing 
1. Prophylaxis management and treatment. 
2. Safe blood , blood product and organ donation 
3. Effectiveness of targeted intervention assessment 
4. Sentinel surveillance 
5. To identify Asymptomatic individuals 
6. To diagnose clinically suspected cases 
7. For peace of mind of patients practicing high risk behavior. 
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RATIONALE 
After viral infection, first antigenemia is observed. It is only after 3 to 8 
weeks that patient will start developing antibodies. Antibodies of IgM 
and IgG are produced. The period before the production of antibody 
where only the antigen persists is called Window period. The first 
antigens to rise are the protein products of the gene Gag (namely -55 
and p24). P24 levels continue to rise along with concomitant 
progression of the disease to AIDS. Antibodies will however persist 
throughout infection. 
We usually check for the Ig A levels in saliva and other secretions. 
IgM is invaluable in contributing to the early detection after needle 
stick injury or during the neonatal period. 
Informed consent is very important prior to all those who undergo HIV 
detection tests.  
Similarly confidentiality is of utmost importance18.  
TESTS 
There are 2 tests that are routinely done for detection of HIV. 
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1. Screening test 
2. Supplemental test 
SCREENING TEST 
Screening tests are used for the purpose of screening donated blood 
and blood product. The most commonly employed method is Enzyme 
linked immunosorbent assay. It is called ELISA. It is a simple 
screening test. It takes about two to three hours to yield the result. 
Simple screening test takes lesser time.  These are called Rapid 
ELISA 
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SUPPLEMENTAL TEST 
Supplemental tests are performed on samples which are reactive in 
screening tests. This is done to confirm the diagnosis of the infection 
in the individual. The supplementary test commonly used is called the 
western blot Immunofluorescence test.  
 
The usual protocol which is followed is, if patient’s serum is reactive 
for one screening test, another screening test with a different antigen 
is used. If that is also reactive, a supplementary test is used. When 
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choosing the ELISA kit, it has to be ensured they have antibodies 
against HIV 1 and HIV 2. 
SPECIMEN: The usual specimen collected is the patients’ blood, 
serum or plasma. This is the best sample. Other specimens are urine 
and other secretions. 
ELISA TESTS 
ELISA tests can be indirect, competitive, sandwich or Capture assay. 
Out of these indirect ELISA is the one which has been used.  In this 
the HIV antigen is usually bound by a covalent bond to the solid 
medium, and the antibodies in the patient’s serum is allowed to flow 
through. If the immunoglobulin binds to specific substrate, it will show 
as a color reaction. 
There are some important technical considerations when interpreting 
the results. 
INTERPRETATION OF RESULTS 
While interpreting the positive results one should always keep in mind 
that screening test reactivity are never used to interpret result as 
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positive. We should keep in mind the possibility of hemolysis, 
repeated freezing, thawing, bacterial contamination and temperature 
of the surrounding. 
We should practically remember some causes of false positive results 
which are autoimmune diseases where there may be multiple 
antibodies. Multiple pregnancies, multiple transfusions, hyper gamma 
globulinemia, antipolysterene antibodies and Hepatitis B 
immunisation.19 
False negative result that is result being negative when the HIV 
infection is present can occur, in window period, laboratory error. 
B.6 JOINT TREATMENT FOR TUBERCULOSIS AND 
HUMAN IMMUNODEFICIENCY 
Ever since the first case report of HIV infection from Chennai, it has 
taken a rampant course throughout India. Along with the course of 
AIDS, there has been a resurgence of Tuberculosis. This has 
mandated for the two national guidelines to include each other in its 
program for a better control. 
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Approximately around 2.31 people suffer from HIV infection in India 
according to surveillance studies in 2009. This led to an increased 
risk of more than 8 times in acquiring tuberculosis in a high endemic 
area like India. With subsequent therapy with HAART or the highly 
active anti-retroviral therapy, a declining trend of the new tuberculosis 
case was observed, but never the less an HIV infected patient, 
remained at a higher risk than HIV negative individual for acquiring 
tuberculosis.  
In Indian literature, the incidence of Tuberculosis in HIV is 
approximately 60 %.The cause of death in many cases has been 
attributed to a pulmonary tuberculosis sequele in a HIV positive 
patient. Even after effective Tuberculosis control, the control of HIV 
worsened and such patients went in for severe T-Cell depletion and 
opportunistic infections. 
The strategies that were employed were, to find and effectively treat 
active tuberculosis. This will break the transmission cycle between 
active individuals and HIV positive individuals. Apart from the TB 
center which gives basic services to identify tuberculosis, it was 
started in HIV testing centers also. Therefore, Tuberculosis testing 
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was started in addition in ART centers, Community centers, NGO 
targeted intervention sites .Counsellors and clinicians were trained to 
give the best possible care for the HIV – TB coinfected individual. 
With HIV – TB co infected individuals to the tune of 60 %, it is 
imperative that a new method of Tuberculosis case finding is needed. 
It is called intensified tuberculosis case finding. It is done in ART 
centers, as once a person gets HIV TB co infection, with his regular 
visits, he can spread TB to many HIV Positive individuals. The ART 
center officers are given special training to carefully recognize the TB 
symptoms in HIV patient and offer him proper diagnosis, treatment 
before he can become a source of infection and start spreading the 
bacilli to poor people, who have come to ART center to seek 
treatment. 
Other centers like community based centers and link center also 
serve the same purpose, hence they must also be trained. 
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INTENSIFIED TB CASE FINDING – ART 
Any HIV positive patients with symptoms of 
1. Cough (both acute and chronic) 
2. Hemoptysis 
3. Pyrexia of unknown origin 
4. Unexplained weight loss, night sweats, loss of appetite 
5. Pleuritic chest pain 
6. Swelling in neck, groin, armpit, and abdomen. 
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Patients with HIV should be under constant surveillance for TB 
All these symptoms must be questioned during  
a. Pre ART registration and follow up 
b. ART initiation 
c. Monthly visits to ART center and follow up. 
d. All patient encounters at ART center 
All the staff not only the medical officer are responsible for tracking 
the symptoms of tuberculosis in HIV positive individual. If any 
suspected patient is found, he is referred immediately to the medical 
officer for treatment. 
On the same day, patient has to be tested for sputum positivity by an 
institutionally designated microscopy center using RNTCP lab form 
with an ART stamp. Chest skiagram is mandatory.20 
The RNTCP technician, then screens the sputum and answers 
directly to the medical officer of ART. The ART medical officer then 
takes a decision, to either treat the infection directly, or to take help of 
the clinicians if required. It is the responsibility of the ART Medical 
officer to manage the opportunistic infections. If once the patient turns 
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out to have sputum smear positivity, then the ART medical officer 
would immediately try and register the patient in DOTS center24.  
SIMPLIFIED CLINICAL FEATURES IN A PATIENT WITH 
HIV 
It is the constitutional symptoms that must first raise the suspicion in 
a HIV positive individual. This is true for both HIV positive and 
negative individual. 
A HIV positive patient with constitutional symptoms is Tuberculosis 
unless proved otherwise.  
TUBERCULOSIS CASE DEFINITIONS 
SPUTUM SMEAR POSITIVE TUBERCULOSIS: - Patient with even 
one smear positive with radiological signs of TB 
SPUTUM SMEAR NEGATIVE TB: -   Patients with both the smear 
negative, and after 14 days antibiotic therapy, shows no response 
and Chest X-ray shows active Tuberculosis. 
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EXTRA PULMONARY TUBERCULOSIS: - It is the involvement of 
organs other than the lung, such as pleura, lymph node, genito 
urinary tract, bones and joints, and the central nervous system.  
Patient with both pulmonary and extra pulmonary features will fall 
under pulmonary TB but his site of extra pulmonary spread will be 
noted. 
BASIC TREATMENT REGIMENS - TUBERCULOSIS 
 
The Numbers in the chart which precede the letters refer to the 
months of treatment. The number in subscript which succeeds the 
letters refer to the doses per week. This is the strength of the ATT 
drugs. 
64 
 
1. INH referred as H – 600 mg 
2. Rifampicin referred as R – 450mg 
3. Pyrazinamide referred as Z – 1500mg 
4. Ethambutol referred as E – 1200 mg 
5. Streptomycin referred as S – 750 mg. 
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Patients who weigh less than 30 kg’s should receive in pediatric 
doses. 
Steroids are indicated in tuberculosis in cases of tuberculous 
meningitis, pericarditis, pleuritic, serositis, and adrenalitis.21 
TREATMENT OF TB IN HIV PATIENTS 
DOTS STRATEGY 
 
Directly observed treatment in short course, at least during the 
intensive phase is the cornerstone in treatment of HIV. First of all 
after categorizing the HIV patient with TB into category 1 and 2, next 
step is to ensure DOTS. A health worker, or a trained observer 
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(DOTS provider) encourages, supports and supervises the patient to 
swallow the tablets. Receiving Anti tuberculous therapy at the right 
dose, at the right time and right dosage is of paramount importance. 
Failure to utilize DOTS, in an HIV positive individual has shown to 
increase case fatality rate. 
PROVISION OF ATT 
ATT is being provided free of cost, in color coded and patient wise 
boxes. There are two boxes, one for intensive phase, and one for 
continuation phase. If a patient is diagnosed as TB in ART center, 
ATT can be initiated in ART center itself. Patient will be provided the 
minimum weekly dose, before he can get shifted to a nearby DOTS 
center. 
PATIENTS WHO ARE ON SECOND LINE ART 
The protease inhibitors interact with rifampicin. Hence patient who 
are taking protease inhibitor based regimen need to be changed on a 
different regimen. 
Rifampicin will increase the need for stepping up the dosage of 
protease inhibitor which will cause increased side effects. 
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NACO has recommended the use of Rifabutin for patients taking 
Lopinavir/ritonavir based ART regimens. Dose of rifabutin is 150mg 
thrice weekly. Side effect profile is very similar to rifampicin23. 
TREATMENT OF HIV IN HIV/ TB COHORT 
The goals of therapy are 
1. Prolongation of life, and improvement of QOL 
2. To decrease viral load to undetectable levels 
3. To increase or normalize the CD4 counts. 
4. To limit drug toxicity 
5. Reduce HIV transmission 
BENEFITS OF ART INITIATION 
It is well known, that ART initiation decreases TB incidence. HIV 
positive patients with CD4 counts less than 350 cells/cubic millimeter 
are at great risk of AIDS related death. Without ART, ATT treatment 
alone would not suffice. The use of HAART is essential for the 
decrease in viral load.22 
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Usually TB treatment with ATT is initiated as it already represents 
WHO clinical stage 3 or 4. 
 
ART treatment is guided on CD4 cell count and the category of 
pulmonary tuberculosis .All patients are started on ATT, then if the 
CD4 count is less than 350 cell/cu mm of blood, then ART is initiated 
as soon as ATT is tolerated. Preferably it is started after 2 weeks, 
before 2 months. The commonly used ART drugs can be divided into 
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First Line regimen of ART in HIV TB co infected individual. 
1. AZT + 3TC + (EFV) (for patients with Hemoglobin >9g/dl) 
Second line alternative regimen 
2. D4T + 3TC + (EFV) 
In special situations TDF or tenofovir is substituted in the regimen. 
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A special note on IRIS 
IRIS 
This is known as immune reconstitution inflammatory syndrome. IRIS 
typically occurs in individuals started on ART, anywhere between 5 
days to months after initiation. It usually presents as 
1. Fever 
2. Worsening of pre-existing lymphadenopathy 
3. Rarely, tracheal compression 
Therapy for serious IRIS reactions are corticosteroids. 
Now we move on to the actual study. 
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MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
SETTINGS 
The study was conducted in the Institute of Internal medicine and 
ART centre at Madras Medical College and Rajiv Gandhi 
Government General Hospital. 
ETHICAL COMMITTEE APPROVAL 
OBTAINED 
STUDY DURATION 
This study was done for a duration for a period of six months. 
STUDY POPULATION 
Patients admitted in medical wards with HIV TB co infection.  
TYPE OF STUDY 
Prospective and observational study of 100 patients   
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SAMPLE SIZE 
100 patients recruited from Institute of Internal medicine and 
antiretroviral center from Rajiv Gandhi Government General Hospital 
Chennai. 
         INCLUSION CRITERIA 
Patients who are HIV infected as evidenced by ELSIA and western 
blot Reactivity, and with clinical features and radiological features of 
tuberculosis. 
EXCLUSION CRITERIA 
Patients who are   
1. HIV negative and TB  
2. Patient not willing for follow up 
3. Patient not willing for the study 
4. Patient who are too sick and moribund  
5. Those who have been diagnosed prior and have already started 
ATT. 
6. MDR and XDR Tuberculosis. 
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DATA COLLECTION AND METHODS  
We examined 100 patients recruited from Institute of Internal 
Medicine, and Anti-retroviral center. Informed consent was obtained 
from each patient and relatives in necessary cases. They were given 
a questionnaire and were subjected to thorough clinical examination. 
Patients were asked to take routine blood investigations like renal 
function tests, liver function tests, CD4 cell count and Chest X-ray 
and sputum examination by Ziehl-Neelson of acid fast bacilli (AFB). 
Histopathological examination of typical granulomatous reaction was 
demonstrated in relevant cases. If extra pulmonary tuberculosis was 
suspected, relevant investigations like ascetic fluid analysis, pleural 
fluid analysis ultrasound abdomen, CT brain, MRI brain and MR 
spectroscopy was taken. All the data was entered in the proforma 
(enclosed). Data was analyzed using Excel data analysis software 
and p value was calculated using paired T test. 
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AGE DISTRIBUTION 
 
 
AGE GROUP 
(Years) 
NO. OF 
CASES 
≤20 2 
21-30 11 
31-40 36 
41-50 35 
≥51 16 
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RANGE OF CD4 CELL COUNT 
 
CD4 COUNT 
(Cells/ cu mm) 
NO. OF 
CASES 
≤100 2 
101-200 14 
201-300 7 
301-400 13 
401-500 10 
≥501 54 
 
 
 
 
 
0 10 20 30 40 50 60
≤100 
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CATEGORY OF TB 
 
 
TUBERCULOSIS 
NO. OF 
CASES 
EXTRAPULMONARY 18 
PULMONARY 82 
 
 
 
 
 
 
 
 
18% 
82% 
CATEGORY OF TB 
EXTRAPULMONARY PULMONARY
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SPUTUM ANALYSIS 
 
 
SPUTUM 
NO. OF 
CASES 
POSITIVE 67 
NEGATIVE 33 
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SPUTUM AFB ANALYSIS IN EXTRAPULMONARY CASES 
 
 
SPUTUM NO. OF EXTRAPULMONARY CASES 
NEGATIVE 18 
POSITIVE 0 
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SPUTUM AFB ANALYSIS IN PULMONARY CASES 
 
 
 
 
 
SPUTUM NO. OF PULMONARY CASES 
NEGATIVE 15 
POSITIVE 67 
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CATEGORY OF TB BASIS CD4 CELL COUNT 
 
CD4 COUNT (Cells/ 
cu mm) 
NO. OF 
EXTRAPULMONARY 
TB CASES 
NO. OF 
PULMONARY 
TB CASES 
0-100 2 0 
101-200 14 0 
201-300 2 5 
301-400 0 13 
401-500 0 10 
≥501 0 54 
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SITE OF TUBERCULOSIS 
 
 
TUBERCULOSIS SITE 
NO. OF 
CASES 
EXTRAPULMONARY PL 10 
EXTRAPULMONARY CNS 5 
EXTRAPULMONARY ABD 2 
EXTRAPULMONARY DIS 1 
PULMONARY . 82 
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SEX DISTRIBUTION 
 
SEX 
NO. OF 
CASES 
MALE 80 
FEMALE 20 
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SEX DISTRIBUTION IN TUBERCULOSIS 
 
SEX TUBERCULOSIS 
NO. OF 
CASES 
MALE EP 13 
MALE P 67 
FEMALE EP 5 
FEMALE P 15 
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RESULTS 
AGE DISTRIBUTION 
In our present study 36 % of patients were in the age group between 
age 31-40 and 35 % of patients were in age group between 41-50 
years. This is in accordance with the long incubation period of HIV. 2 
% were below the age of 20 years and 16 % of the patients were 
above 51. 
SEX DISTRIBUTION 
80 % of the study population were males and 20 % were females. 67 
patients among the male population had pulmonary Tb whereas only 
15 patients among the female population were pulmonary 
tuberculosis. Likewise, extra pulmonary TB was seen in 13 male 
patients and 5 female patients.  
.CD4 CELL COUNT RANGE 
 The CD4 cell count ranged from 59 (lowest) to 711 cells /cu mm. The 
values were arbitrarily arranged with a difference of 100 cells/cu mm. 
54 % of the patient had a CD4 cell count more than 500 cells /cu mm. 
16 % of patients had CD4 count less than 200 cell/cu mm.  
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SPUTUM ANALYSIS 
67 % of the patients in our present study proved to be sputum 
positive for acid fast stain. All the patients with extra pulmonary 
tuberculosis were sputum negative. This goes in accordance with 
many other studies, sputum analysis is not a sensitive investigation 
for extra pulmonary tuberculosis. For pulmonary tuberculosis, with 
CD4 cell count above 200 cells/cu mm of blood, sputum AFB is still a 
sensitive investigation to detect pulmonary tuberculosis. 
TB CD4 RELATIONSHIP 
CD4 COUNT 
(Cells/ cu 
mm) 
FOR NO. OF 
EXTRAPULMONARY 
TB CASES 
FOR NO. OF 
PULMONARY TB 
CASES 
Mean 3 13.66666667 
SD 5.477225575 20.44178727 
P value 0.026 0.052 
It tells us that the p-value for a one-tail test would be 0.1564, make 
the -1 the exponent of the 6.Then you will see the more familiar 
0.156x6^-1. This is the number 0.026. Extra pulmonary is Significant 
which is less than alpha = 0.05. 
The majority of the patients having CD4 cell count more than 200 in 
the present study demonstrated that they had pulmonary 
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tuberculosis. Patients who had a count between 350 to 500 cells /cu 
mm, demonstrated atypical sites involved in the lungs for pulmonary 
tuberculosis. Most of the patients (18 %) who had extra pulmonary 
tuberculosis had CD4 cell count less than 200 cells/cu mm.2 patients 
just above 200  cells/ cu mm, had extra pulmonary manifestations. 
The threshold level of CD4 count of 200 cells/cu mm for extra 
pulmonary tuberculosis is statistically proved significant p value by 
paired t test. 
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DISCUSSION 
 
In India, tuberculosis prevalence was stable and was getting under 
control till the HIV epidemic started. HIV became a strong risk factor 
for TB resurgence. Among the opportunistic infections which affected 
People living with HIV and AIDS, Tuberculosis was the commonest of 
them all. Tuberculosis could affect HIV positive individual with any 
degree of immunosuppression. As explained above the in the review 
of literature, tuberculosis accelerates Human immunodeficiency virus 
infection and HIV accelerates TB progression. The degree of 
immunosuppression is evidenced by CD4 cell count. In our study, 
100 patients were enrolled from medical wards and antiretroviral 
center who satisfied the inclusion criteria for the study. Majority of 
them, 80% were male patients and (20 %) were female patients. Most 
of the males, were drivers by profession and the females were home 
makers. The commonest mode of transmission was by Sexual 
transmission. This is in concordance with the other studies 
suggesting that HIV in India spreads more by heterosexual 
transmission than by homosexual transmission.  CD4 cell count for 
these patients ranged from 59 to 711 cells per cubic millimeter. The 
patients above 500 cells per cubic millimeter of blood, showed 
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predominantly tuberculosis very similar to patients who had 
tuberculosis and were HIV negative. Predominantly upper lobe was 
involved in post primary stage. In patients who had CD4 cell count 
between 350 and 500 cells per cubic millimeter of blood, most of the 
patients had atypical locations of the post primary Tb, having 
predominant involvement of the lower lobe. In patients whose CD4 
count was less than 200 cells per cubic millimeter of blood, all of 
them had extra pulmonary tuberculosis in our study. Commonest 
form of extra pulmonary tuberculosis was pleural tuberculosis. All of 
them presented with pleural effusion, majority was on the right side.  
The sputum analysis revealed that all extra pulmonary tuberculosis 
cases were negative for acid fast stain. Among the pulmonary 
tuberculosis patients, sputum was positive in 82 % patient and 
negative in 18 %. According to our study, sputum analysis still proves 
a cost effective method to analyze the tuberculosis in HIV positive 
individuals who has CD4 cell count more than 200 cells per cubic 
millimeter of blood. Very closely related study done by Jaryal et al in 
2011 showed that extra pulmonary TB were common manifestation in 
HIV positive individuals, which is not in accordance with our study. In 
his study, CNS spread of tuberculosis is the most common extra 
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pulmonary manifestation. In another study Brig S K Sharma et al, the 
commonest extra pulmonary manifestation was in lymph nodes. CD4 
cell count seems to play pivotal role in the variation in clinical 
manifestations of tuberculosis in HIV infected individuals. CD4 cell 
count demonstrates the degree of immunosuppression. A threshold 
value of 200 cells per cubic millimeter was identified as the value 
below which most of the manifestations of tuberculosis was extra 
pulmonary.  This demonstrates that CD4 count should be used as a 
branch point while treating HIV TB coinfection. A value below 200 
cells per cubic millimeter of should prompt us to search for extra 
pulmonary tuberculosis. 
 
LIMITATIONS OF THE STUDY 
1. The data was collected from a single center. 
2. The sample size is small for HIV TB coinfected population. 
3. Potential for Bias and hence inaccuracy. 
Large multi-centric studies in future prospective studies are needed to 
fully ascertain the accuracy of the above findings. 
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CONCLUSION 
   
Tuberculosis is the commonest opportunistic infection among people 
living with HIV and AIDS (PLHA). 
Among the spectrum of Tuberculosis possible in HIV infected 
individuals, Pulmonary Tuberculosis is more common than extra 
pulmonary tuberculosis.  
The sensitivity of sputum smear in detecting pulmonary tuberculosis 
in PLHA is decreased as compared to Non HIV infected individuals. 
Above CD4 count of 200 cells per cubic millimeter, most of the 
patients were suffering from pulmonary tuberculosis. Below the CD4 
count of 200 cells per cubic millimeter, patients were suffering from 
extra pulmonary tuberculosis predominantly. 
Among the patients in the study suffering from extra pulmonary 
Tuberculosis, the most common site was Pleura. 
CD4 cell count can be a cost effective method in guiding us to identify 
the organ commonly affected by tuberculosis in HIV positive 
individuals and in future may help in formulating an algorithm for HIV 
TB coinfection. 
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ABBREVIATIONS 
 
HIV  - Human Immunodeficiency Virus 
AIDS  - Acquired Immunodeficiency Deficiency Syndrome 
ART  - Antiretroviral Therapy  
DOTS - Direct Observation and Treatment in Short course  
WHO  - World Health Organization  
LAM   - Lipo Arabino Mannan 
TLR  -  Toll Like Receptor 
CD   - Cluster of Differentiation 
TNF   -  Tumor Necrosis Factor 
NK    - Natural Killer Cells  
NOS  - Nitric Oxide Synthase 
ELISA - Enzyme Linked Immuno Sorbant Assay 
LAC  - Link ART Center 
RNTCP - Revised National Tuberculosis Control Programme 
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PROFORMA 
PATIENT DETAILS: 
Name:     Age:   Sex:   
IP No.: 
ON ADMISSION: 
Main Complaints:  
 
 
H/o cough           
H/o sputum 
H/o hemoptysis 
H/o weight loss 
H/o breathlessness 
H/o orthopnea/PND 
H/o hematemesis 
H/o melena 
H/o seizures 
H/o altered sensorium 
H/o altered sleep pattern 
H/o chest pain 
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H/o abdominal pain 
H/o fever 
H/o constipation            
H/o intake of any drugs 
 
 
Significant Past History:    HIV diagnosed on  
ART number 
TB diagnosed by   
CD4 Cell count 
CLINICAL EXAMINATION: 
Pulse:      BP: 
RR:       Temp: 
Pallor:      Icterus: 
CVS:       RS: 
P/A: 
CNS: 
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INVESTIGATIONS: 
Hemogram: 
Renal Function Test: 
Liver Function Test: 
BT/CT/PT/INR: 
Blood Grouping: 
CD4 Cell Count: 
ECG: 
Imaging: 
CXR: 
USG Abdomen: 
CT Chest: 
CT Abdomen: 
CT Brain: 
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DIGITAL RECEIPT 
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ஆராய்ச்சிதகவல்தாள் 
 
சென்னை இராஜிவ் காந்தி அரசு ச ாது மருத்துவ மனையில் “எச்.ஐ.வி 
ந ாயாளிகள் காெ ந ாய் சவளிப் ாடுகளும் மற்றும் CD4 எண்ணிக்னகயும் 
அதன் சதாடர்பும்”  ற்றிய ஒரு ஆராய்ச்ெி  னடச ற்று வருகிறது. 
 . 
 ீங்கள் இந்த ஆய்விற்கு தகுதியாைவர்களாக இருக்கும்  ட்ெத்தில் தங்களின் 
மருத்துவ சுயவிவரத்னதயும், ஆய்வக  ாிநொதனை அறிக்னகயும் மற்றும் 
கதிாியக்க அறிக்னகயும் ஆய்வு ந ாக்கங்களுக்காக  யன் டுத்த டும். இது 
உங்களுனடய இறுதி அறிக்னக அல்லது நமலாண்னமனய  ாதிக்காது. 
 
 ீங்களும் இந்த ஆராய்ச்ெியில்  ங்நகற்க  ாங்கள் விரும்புகிநறாம். 
முடிவுகனள அல்லது கருத்துக்கனள சவளியிடும் ந ாநதா அல்லது 
ஆராய்ச்ெியின் ந ாநதா தங்களது ச யனரநயா அல்லது 
அனடயாளங்கனளநயா சவளியிடமாட்நடாம் என் னதயும் சதாிவித்துக் 
சகாள்கிநறாம். 
 
இந்த ஆராய்ச்ெியில்  ங்நகற் து தங்களுனடய விருப் த்தின் ந ாில் தான் 
இருக்கிறது. நமலும்  ீங்கள் எந்ந ரமும் இந்த ஆராய்ச்ெியிலிருத்து 
 ின்வாங்கலாம் என் னதயும் சதாிவித்துக்  சகாள்கிநறாம். 
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இந்த ெிறப்புப்  ாிநொதனை களின் முடிவுகனள ஆராய்ச்ெியின் ந ாது 
அல்லது ஆராய்ச்ெியின் முடிவில் தங்களுக்கு அறிவிப்ந ாம் என் னதயும் 
சதாிவித்துக் சகாள்கிநறாம். 
 
ஆராய்ச்ெியாளர்னகசயாப் ம்  ங்நகற் ாளர்னகசயாப் ம் 
 
 
நததி: 
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INFORMATION SHEET 
We are conducting a study on “SPECTRUM OF TUBERCULOSIS IN 
HIV PATIENTS AND ITS CO-RELATION TO CD4 COUNT” among 
patients attending Rajiv Gandhi Government General Hospital, 
Chennai and for that your specimen may be valuable to us. 
The purpose of this study is  
1. To analyze the different manifestations of TB in HIV positive 
patients. 
2. To analyze if the manifestations have a co-relation to the degree of 
immunosuppression. 
We are selecting certain cases and if you are found eligible, we may 
be using your information which in any way do not affect your final 
report or management. 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally  
Information will be shared. 
Taking part in this study is voluntary. You are free to decide whether 
to participate in this study or to withdraw at any time; your decision 
will not result in any loss of benefits to which you are otherwise 
entitled. 
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The results of the special study may be intimated to you at the end of 
the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
Signature of Investigator   Signature of Participant 
Date : 
Place :  
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ஆராய்ச்சிஒப்புதல்கடிதம் 
 
ஆராய்ச்ெிதனலப்பு:    
“எச்.ஐ.விந ாயாளிகள்காெந ாய்சவளிப் ாடுகளும்மற்றும் CD4 
எண்ணிக்னகயும்அதன்சதாடர்பும்”. 
ஆய்வு ினலயம் :ச ாது லமருத்துவத்துனற 
   சென்னைமருத்துவக்கல்லூாி 
   சென்னை - 600003 
ச யர்:   நததி: 
வயது:   உள்ந ாயாளிஎண்: 
 ால்:   ஆராய்ச்ெிநெர்க்னகஎண்: 
        
ஆய்வு விவரங்கனள எைது சொந்த சமாழியில் எைக்கு விளக்கிைார். எைக்கு 
ெந்நதகம் நகட்க ஒரு வாய்ப்பும்,  அதற்கு தகுந்த  தில்களும் வழங்கப் ட்டது. 
        
 
 ான் இந்த ஆய்வில் தன்ைிச்னெயாகதான்  ங்கநகற்கிநறன். எந்த 
காரணத்திநலா எந்த கட்டத்திலும் எந்த ெட்டெிக்கலுக்கும் உட் டாமல்  ான் 
இவ்வாய்வில் இருந்து விலகி சகாள்ளலாம் என்றும் அறிந்து சகாண்நடன். 
            
 
இந்த ஆய்வு ெம் ந்தமாகநவா, இனத ொர்ந்த நமலும் ஆய்வு நமற்சகாள்ளும் 
ந ாதும் இந்த ஆய்வில்  ங்குச றும் மருத்துவர் என்னுனடய மருத்துவ 
அறிக்னககனள  ார் தற்க்கு என் அனுமதி நதனவ இல்னல எை அறிந்து 
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சகாள்கிநறன்.  ான் ஆய்வில் இருந்து விலகிக் சகாண்டாலும் இது 
ச ாருந்தும் எை அறிகிநறன்.        
            
 
இந்த ஆய்வின் மூலம் கினடக்கும் தகவல்கனளயும்,  ாிநொதனை 
முடிவுகனளயும் மற்றும் ெிகிச்னெ சதாடர் ாை தகவல்கள்கனளயும் 
மருத்துவர் நமற்சகாள்ளும் ஆய்வில்  யன் டுத்திக்சகாள்ளவும் அனத 
 ிரசுாிக்கவும்  ான் முழுமைதுடன் ஆய்வில்  ங்நகற்க ஒப்புக்சகாள்கிநறன். 
 ான் மருத்துவாிடம் உண்னமயாக இருப்ந ன் எை உறுதியளிகிநறன். 
            
 
 
ஆய்வாளாின்னகசயாப் ம்    ங்நகற் ாளர்னகசயாப் ம் 
ஆய்வாளாின்ச யர்:     ங்நகற் ாளர்ச யர்/முகவாி 
டாக்டர்.  ரத்ராஜ்கிடாம் ி 
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PATIENT CONSENT FORM 
Study Detail : “SPECTRUM OF TUBERCULOSIS IN HIV 
PATIENTS AND ITS CO-RELATION TO CD4 COUNT” 
Study Centre : Rajiv Gandhi Government General Hospital, 
Chennai. 
Patient’s Name :  
Patient’s Age :  
In Patient Number :  
Patient may check (☑) these boxes 
       I confirm that I have understood the purpose of procedure for the 
above study. I have the opportunity to ask question and all my 
questions and doubts have been answered to my complete 
satisfaction.          
       I understand that my participation in the study is voluntary and 
that I am free to withdraw at any time without giving reason, without 
my legal rights being affected. 
      I understand that I will not be eligible for any compensation . 
            
       I understand that sponsor of the clinical study, others working on 
the sponsor’s behalf, the ethical committee and the regulatory 
authorities will not need my permission to look at my health records, 
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both in respect of current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study I agree to 
this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any 
data or results that arise from this study.      
       I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperate with the 
study team and to immediately inform the study staff if I suffer from 
any deterioration in my health or well-being or any unexpected or 
unusual symptoms.         
       I hereby consent to participate in this study    
       I hereby give permission to undergo complete clinical 
examination and diagnostic tests including hematological, 
biochemical, radiological tests.       
 
  
Signature/thumb impression   Signature of Investigator 
Patient’s Name and Address:  Study Investigator’s Name 
       Dr.BHARATH RAJ KIDAMBI 
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MASTER CHART 
S.NO AGE SEX CD4 COUNT TUBERCULOSIS SPUTUM 
1 29 F 159 EP - 
2 18 M 143 EP - 
3 45 M 504 P + 
4 47 M 159 EP - 
5 54 M 163 EP - 
6 43 M 601 P + 
7 26 F 112 EP - 
8 39 M 523 P + 
9 51 M 298 P - 
10 25 M 178 EP - 
11 38 M 179 EP - 
12 34 M 631 P + 
13 51 M 111 EP - 
14 34 F 710 P + 
15 52 M 145 EP - 
16 33 M 109 EP - 
17 53 M 303 P - 
18 51 M 401 P + 
19 39 M 351 P - 
20 52 M 495 P + 
21 45 M 583 P + 
22 46 M 572 P + 
23 29 F 198 EP - 
24 48 M 521 P + 
25 38 M 359 P - 
26 44 M 411 P + 
27 53 M 378 P + 
28 43 M 598 P + 
29 37 M 632 P + 
30 49 M 471 P + 
31 41 M 711 P + 
32 52 M 359 P - 
33 36 M 391 P + 
34 46 M 377 P + 
35 45 F 653 P + 
36 49 F 548 P + 
37 47 M 298 P - 
38 53 M 257 P - 
39 44 M 501 P - 
40 54 M 365 P - 
41 38 M 609 P + 
42 24 M 59 EP - 
43 31 M 410 P + 
44 28 F 423 P + 
45 35 F 627 P + 
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46 47 F 710 P + 
47 39 M 301 P - 
48 19 M 156 EP - 
49 45 M 589 P + 
50 37 M 278 P - 
51 24 M 178 EP - 
52 35 M 672 P + 
53 29 F 375 P + 
54 34 M 647 P + 
55 39 M 491 P + 
56 37 M 490 P + 
57 31 F 221 EP - 
58 49 M 616 P + 
59 52 M 201 EP - 
60 51 M 311 P - 
61 44 M 517 P + 
62 41 M 406 P + 
63 33 F 539 P + 
64 38 M 572 P + 
65 46 M 628 P + 
66 31 M 617 P + 
67 43 M 602 P + 
68 48 F 622 P + 
69 39 M 642 P + 
70 32 M 662 P + 
71 47 M 682 P + 
72 49 M 702 P + 
73 36 M 722 P + 
74 27 F 97 EP - 
75 39 F 556 P + 
76 51 M 270 P - 
77 47 M 578 P + 
78 30 F 611 P + 
79 44 M 667 P + 
80 40 F 656 P + 
81 31 M 641 P + 
82 53 M 327 P - 
83 26 M 139 EP - 
84 36 M 701 P + 
85 45 M 721 P + 
86 41 F 741 P + 
87 41 M 761 P + 
88 48 M 560 P - 
89 34 M 593 P + 
90 38 M 649 P + 
91 52 M 478 P + 
92 47 F 623 P + 
93 34 M 643 P + 
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94 38 M 391 P + 
95 46 F 683 P + 
96 44 M 703 P + 
97 41 M 723 P + 
98 37 M 743 P + 
99 32 M 521 P + 
100 35 M 577 P + 
 
 
S.NO AGE SEX 
CD4 
COUNT 
TUBERCULOSIS SPUTUM SITE 
1 29 F 159 EP - PL 
2 18 M 143 EP - ABD 
3 47 M 159 EP - PL 
4 54 M 163 EP - CNS 
5 26 F 112 EP - CNS 
6 25 M 178 EP - PL 
7 38 M 179 EP - PL 
8 51 M 111 EP - PL 
9 52 M 145 EP - ABD 
10 33 M 109 EP - PL 
11 29 F 198 EP - CNS 
12 24 M 59 EP - DIS 
13 19 M 156 EP - PL 
14 24 M 178 EP - CNS 
15 31 F 221 EP - PL 
16 52 M 201 EP - PL 
17 27 F 97 EP - CNS 
18 26 M 139 EP - PL 
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KEY TO MASTER CHART 
 
M - Male 
F - Female 
P - Pulmonary tuberculosis 
EP - Extra pulmonary Tuberculosis 
PL - Pleura 
CNS - Central Nervous System 
ABD - Abdomen 
DIS - Disseminated 
“+” - Positive for acid fast bacilli 
“-“ - Negative for acid fast bacilli 
 
